Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: "Service (economics)"
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"CADTH Canadian Drug Expert Committee"
Showing
1
-
13
of
13
Search:
'"Service (economics)"'
,
query time: 0.08s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
CADTH Canadian Drug Expert Committee final recommendation: Omalizumab -- resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.) : indication: asthma
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Insurance, Pharmaceutical
Services
/
economics
...
”
Read Now
2
CADTH Canadian Drug Expert Committee final recommendation: Omalizumab -- resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.) : indication: asthma
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Insurance, Pharmaceutical
Services
/
economics
...
”
Read Now
3
CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Insurance, Pharmaceutical
Services
/
economics
...
”
Read Now
4
CADTH Canadian Drug Expert Committee final recommendation: Sapropterin -- resubmission (Kuvan -- BioMarin Pharmaceuticals Canada Inc.) : indication: to reduce blood phenylalanine l...
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Insurance, Pharmaceutical
Services
/
economics
...
”
Read Now
5
CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Insurance, Pharmaceutical
Services
/
economics
...
”
Read Now
6
CADTH Canadian Drug Expert Committee final recommendation: Sapropterin -- resubmission (Kuvan -- BioMarin Pharmaceuticals Canada Inc.) : indication: to reduce blood phenylalanine l...
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Insurance, Pharmaceutical
Services
/
economics
...
”
Read Now
7
CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Insurance, Pharmaceutical
Services
/
economics
...
”
Read Now
8
CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Insurance, Pharmaceutical
Services
/
economics
...
”
Read Now
9
CADTH Canadian Drug Expert Committee recommendation: Migalastat (Galafold -- Amicus therapeutics) : indication : Fabry disease
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Insurance, Pharmaceutical
Services
/
economics
...
”
Read Now
10
CADTH Canadian Drug Expert Committee recommendation: Migalastat (Galafold -- Amicus therapeutics) : indication : Fabry disease
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Insurance, Pharmaceutical
Services
/
economics
...
”
Read Now
11
CADTH Canadian Drug Expert Committee recommendation: Tenofovir alafenamide (Vemlidy -- Gilead Sciences Canada, Inc.) : indication : chronic hepatitis B.
Published 2018
CADTH
Subjects:
“
...Insurance, Pharmaceutical
Services
/
economics
...
”
Read Now
12
CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus-Hoffmann-La Roche Limited) : indication : management of adult patients with early primary progressive mult...
Published 2018
CADTH
Subjects:
“
...Insurance, Pharmaceutical
Services
/
economics
...
”
Read Now
13
CADTH Canadian Drug Expert Committee recommendation: Netupitant/palonosetron (Akynzeo -- Purdue Pharma) : indication : chemotherapy-induced nausea and vomiting
Published 2018
CADTH
Subjects:
“
...Insurance, Pharmaceutical
Services
/
economics
...
”
Back
Narrow Search
Remove Filters
Clear Filter
Author: CADTH Canadian Drug Expert Committee
Year of Publication
From:
To:
Classification
330 - Economics
13
610 - Medicine & health
13
140 - Specific philosophical schools
2
700 - The arts; fine & decorative arts
2
Language
English
13
Collection
National Center for Biotechnology Information
13
Author
CADTH Canadian Drug Expert Committee
Canadian Agency for Drugs and Technologies in Health
13
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=author_facet%3A%22CADTH+Canadian+Drug+Expert+Committee%22&lookfor=%22Service+%28economics%29%22&type=AllFields
Send by Email
×
Loading...